REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a

REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. Recent Business Highlights Initiated clinical study to support COVID-19 510(k) submission for clearance of the Talis One® systemPresented positive data at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) annual meeting differentiating the planned Talis One test menu Development-stage chlamy

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platf

Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a molecular point-of-care (POC) test system with time to result in less than 30 minutes Ability to effectively lyse challenging fungal pathogens, including Candida, in under four minutes on Talis One® system positions Company to develop POC vaginal infection panel REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels. Results from these studies, presented in poster sessions at the 2023 IDSOG Annual Meeting in Denver, Colorado, support Ta

REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In order to regain compliance, the Company's common stock was required to maintain a closing bid price of at l

REDWOOD CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will effect a 1-for-15 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Reverse Stock Split"), effective at 5:00 p.m. Eastern time on July 5, 2023 (the "Effective Time"). The Company's common stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on July 6, 2023. At the Company's ann

REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director. "Heiner's entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is

REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced a business update and reported financial results for the first quarter ended March 31, 2023. Business Update Established ability to manufacture cartridges and instruments that puts us on a path to meaningful margins at scale, at the pace and quality needed to execute the company's business strategyPrioritized development of four Talis One® test panels to address significant unmet needs in the w

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical's w

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

3 - Talis Biomedical Corp (0001584751) (Issuer)

4 - Talis Biomedical Corp (0001584751) (Issuer)

BofA Securities downgraded Talis Biomedical from Neutral to Underperform and set a new price target of $3.00

JP Morgan downgraded Talis Biomedical from Neutral to Underweight and set a new price target of $7.00 from $10.00 previously

BTIG Research downgraded Talis Biomedical from Buy to Neutral

Piper Sandler downgraded Talis Biomedical from Overweight to Neutral and set a new price target of $9.00

JP Morgan downgraded Talis Biomedical from Overweight to Neutral and set a new price target of $10.00 from $17.00 previously

Piper Sandler initiated coverage of Talis Biomedical with a rating of Overweight and set a new price target of $17.00

Bank of America initiated coverage of Talis Biomedical with a rating of Neutral and set a new price target of $14.00

JPMorgan Chase & Co. initiated coverage of Talis Biomedical with a rating of Overweight and set a new price target of $18.00

BTIG Research initiated coverage of Talis Biomedical with a rating of Buy and set a new price target of $18.00

Talis Biomedical (NASDAQ:TLIS) reported quarterly losses of $(7.39) per share. This is a 51.22 percent increase over losses of $(15.15) per share from the same period last year. The company reported $195.00 thousand in sales this quarter. This is a 24.12 percent decrease over sales of $257.00 thousand the same period last year.

Shares of Beyond Air, Inc. (NASDAQ:XAIR) dipped during Tuesday’s session following weak quarterly results. Beyond Air posted a quarterly loss of 51 cents per share, versus market estimates of 51 cents per share. The company’s quarterly sales came in $239,000, versus expectations of $480,000. Beyond Air shares fell 37.3% to $1.2701 on Tuesday. Here are other stocks moving in today's session. Gainers BioCardia, Inc. (NASDAQ:BCDA) shares jumped 235.8% to $1.34 after the company announced the FDA approval of its Phase 3 clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. reAlpha Tech Corp. (NASDAQ:AIRE) shares surged 67.4% to

Talis Biomedical Corp (NASDAQ:TLIS) shares are trading higher by 30% to $7.03 Tuesday morning after the company announced it is exploring strategic options to boost shareholder value due to current market conditions. What Happened? Talis Biomedical formed a special committee to consider various alternatives like financing, mergers or asset divestiture. To cut costs, the company is reducing its workforce by 90% and consolidating operations in Chicago. Despite this, revenue decreased significantly in third-quarter 2023 compared to the same period last year, but operating expenses and net losses have also decreased. They've disclosed cash reserves of $88.0 million as of September 30. As the

U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ:AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter financial results. Azenta posted adjusted earnings of 13 cents per share, beating market estimates of 2 cents per share. The company’s quarterly sales came in $172.36 million versus estimates of $163.9 million. Azenta shares rose 15.1% to $55.05 on Tuesday. Here are some big stocks recording gains in today’s session. Talis Biomedical Corporation (NASDAQ:TLIS) shares rose 33.4% to $7.19 as the company announced exploration of strategic alternatives and cost reduction plan to preserve cash.

  Friday's session saw 169 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Bristol-Myers Squibb (NYSE:BMY) was the largest firm by market cap to set a new 52-week low. Blue Star Foods (NASDAQ:BSFC) was the smallest company in terms of market cap to set a new 52-week low. PTC Therapeutics (NASDAQ:PTCT)'s stock fell the most, as it traded down 31.29% to reach a new 52-week low. Prelude Therapeutics (NASDAQ:PRLD)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. On Friday, the following stocks set new 52-week lows: Bristol-Myers Squibb (NYSE:BMY) stock dropped to a yearly low on Friday of $58.92. Shares traded down

  On Tuesday morning, 164 companies achieved new lows for the year. 52-Week Low Highlights: NextEra Energy (NYSE:NEE) was the largest firm by market cap to set a new 52-week low. SenesTech (NASDAQ:SNES) was the smallest company in terms of market cap to set a new 52-week low. WeWork (NYSE:WE) saw the largest move of the companies, as shares plummetted 3189.55% to hit a new 52-week low. Tarena International (NASDAQ:TEDU)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low. Here is a list of stocks that set new 52-week lows on Tuesday: NextEra Energy (NYSE:NEE) stock dropped to a yearly low on Tuesday of $65.95. Shares traded down 1.0

BTIG has decided to maintain its Sell rating of Talis Biomedical (NASDAQ:TLIS) and raise its price target from $0.35 to $5.00. Shares of Talis Biomedical are trading down 4.35% over the last 24 hours, at $6.81 per share. A move to $5.00 would account for a 26.58% decrease from the current share price. About Talis Biomedical Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19. About Analyst Ratings Analysts work in banking and fin